Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer
Cost effectiveness data already support BRCA1/2 screening for EOC with clear implications for cancer prevention. On the basis of this model, primary tumor testing leads to a 2.67-fold increase in testing with an incremental cost of $1500, supporting this strategy as a cost-effective way to improve BRCA testing.
Authors
- Kenneth J. Smith (ORCID: https://orcid.org/0000-0001-8088-566X)
- Sarah E. Taylor (ORCID: https://orcid.org/0000-0002-1385-1707)
- Ronald J. Buckanovich (ORCID: https://orcid.org/0000-0002-5665-9790)
- Sarah Bell (ORCID: https://orcid.org/0000-0002-9455-5108)
- Robert P. Edwards (ORCID: https://orcid.org/0000-0003-0370-1390)
- L. Phuong (ORCID: https://orcid.org/0000-0002-7486-4974)
- Heidi Donovan (ORCID: https://orcid.org/0000-0002-4889-8644)
- Shannon Rush (ORCID: https://orcid.org/0000-0003-2310-7137)
Institutions
- University of Pittsburgh (US)
- Magee-Womens Hospital (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1097/coc.0000000000001187
- Citations
- 2
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.63